skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Introduction

Two key marketed drugs, Advair and Symbicort, will face erosion in sales due to the emergence of Breo and other generics emerging from the pipeline. Datamonitor Healthcare has provided an in-depth analysis of key marketed products in the US, Japan, and five major EU markets, including an assessment of product positioning in the face of pipeline competition and an evaluation of clinical and commercial drug attributes.

How will our asthma marketed drugs report benefit you?

  • Gain competitive insight
    Access detailed analyses of key marketed drugs within asthma, including an assessment of product positioning in the face of pipeline competition and an evaluation of commercial and clinical drug attributes to determine competitiveness in the market.
  • Understand market share
    Explore how the emergence of Breo and other generics will affect sales of established drugs such as Advair and Symbicort, allowing you to gain a better understanding of your position within the market.
  • Identify driving forces behind the asthma market
    Examine how novel therapies such as Breo, the first once-daily inhaled corticosteroid/long-acting beta 2 agonist, and Xolair, the only biologic for asthma, are positioned within the market so that you can identify what factors are critical for commercial success.

Key questions answered

  • What clinical trials led to regulatory approval of key marketed brands?
  • What factors will enable marketed brands to resist generic erosion?
  • Will GlaxoSmithKline retain its dominance within the asthma market?
http://http//www.datamonitorhealthcare.com/files/2014/07/Asthma-Marketed-Drugs-18.06.2014-19.pdf

Read also

  • Biomedtracker: see the drug development process through anal...

    Key Potential Drug Launches in 2022

    Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

  • Biomedtracker: see the drug development process through anal...

    2020 Deal-Making Roundup

    Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

    Topics Drug Review Coronavirus

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    2021 Post-ASCO Insights and Analysis

    The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: